DMR Procedure

PROCEDURE3 trials

Sponsors

Fractyl Health Inc., Wang Siqi, Fractyl Laboratories, Inc.

Conditions

Diabetes Mellitus, Type 2Noninsulin-Dependent Diabetes MellitusTreatment diabetesType 2 Diabetes Mellitus

Unknown Phase

Evaluation of Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes

Active, not recruitingNL-OMON44146

Fractyl Laboratories, Inc.Treatment diabetes

Start: 2015-07-13Target: 20Updated: 2024-04-23

Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)

CompletedNCT02879383

Fractyl Health Inc.Diabetes Mellitus, Type 2, Noninsulin-Dependent Diabetes Mellitus

Start: 2017-03-01End: 2019-12-20Updated: 2024-02-14

Research on Changes in Intestinal Barrier Function and Gut Microbiome in Patients With Type 2 Diabetes After Duodenal Mucosal Resurfacing (DMR)

Not yet recruitingNCT06385704

Wang SiqiType 2 Diabetes Mellitus

Start: 2024-06-01End: 2025-12-01Target: 100Updated: 2024-04-30

Related Papers

Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial

Gut2021-02-17104 citations